Fe-MoS 2 Nanozymes Combined with Antagonistic Bacteria for the Inhibition of Agrobacterium tumefaciens Growth and Biofilm Formation
Source abstract
Abstract
Agrobacterium tumefaciens ( A. tumefaciens ) underlies the pathogenesis of crown gall disease and is characterized by tumor-like gall formation on the stems and roots of a wide variety of economically important plant species. It is necessary to explore anti- A. tumefaciens agents due to the limited availability of current treatments. In this study, Fe,S-decorated polyoxometalate-based molybdenum disulfide nanosheet (Fe-MoS 2 NS) nanozymes were designed and synthesized to efficiently act against A. tumefaciens . Based on antagonistic bacteria (AT-11) from soil with a high infection rate of A. tumefaciens, the isolated strain presents anti- A. tumefaciens property, and Fe-MoS 2 -bound AT-11 exhibited excellent peroxidase (POD)-like activity for specifically inhibiting the growth and biofilm formation of A. tumefaciens . In addition, electron transfer between Fe 2+ /Fe 3+ and Mo 4+ /Mo 6+ provided more active sites, further increasing the POD-like catalytic activity based on Fenton-like mechanisms, amplifying the chemodynamic therapy potential. Compared to MoS 2, Fe-MoS 2 exhibited a 37.1-fold increase in the POD-like catalytic activity. Fe-MoS 2 combined with AT-11 demonstrated a remarkable synergistic effect against A. tumefaciens with a minimum fungicidal concentration value of 15 μg/mL and significantly reduced the biofilm formation with 15 μg/mL concentration while preserving AT-11 species. The research results indicated that A. tumefaciens inactivation began with membrane rupture, followed by the oxidation and leakage of intracellular substances. Moreover, Fe-MoS 2 inhibits tumor formation on the tomato stem when treatments were applied after A. tumefaciens infection to wounded tissues. This study demonstrated that Fe-MoS 2 can serve as an effective and economical bactericide for an efficient biocontrol of crown gall disease with good biocompatibility and low cost.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Advanced Photocatalysis Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Life Science and Technology
Kunming University of Science and Technology
References (47)
Show source-provided references
1. 10.1007/978-0-387-72290-0_110.1007/978-0-387-72290-0_1 ↗
2. 10.1080/13102818.2020.185872210.1080/13102818.2020.1858722 ↗
3. 10.1073/pnas.060036610310.1073/pnas.0600366103 ↗
4. 10.1351/PAC-CON-08-07-0310.1351/PAC-CON-08-07-03 ↗
5. 10.1094/PDIS-94-8-1064C10.1094/PDIS-94-8-1064C ↗
6. 10.1007/82_2018_8510.1007/82_2018_85 ↗
7. 10.1007/s42161-018-00211-410.1007/s42161-018-00211-4 ↗
8. 10.1007/s13313-020-00682-z10.1007/s13313-020-00682-z ↗
9. 10.1079/9781845934927.000110.1079/9781845934927.0001 ↗
10. 10.3389/fpls.2014.0017610.3389/fpls.2014.00176 ↗
11. 10.1016/j.pestbp.2020.02.01210.1016/j.pestbp.2020.02.012 ↗
12. 10.2478/v10045-012-0075-710.2478/v10045-012-0075-7 ↗
13. 10.1079/9781845930257.000010.1079/9781845930257.0000 ↗
14. 10.3389/fmicb.2019.0289410.3389/fmicb.2019.02894 ↗
15. 10.1016/j.jcis.2023.10.05010.1016/j.jcis.2023.10.050 ↗
16. 10.1002/adfm.20250443410.1002/adfm.202504434 ↗
17. 10.1016/j.snb.2024.13622610.1016/j.snb.2024.136226 ↗
18. 10.1007/s11426-024-2592-410.1007/s11426-024-2592-4 ↗
19. 10.1002/anie.20070454610.1002/anie.200704546 ↗
20. 10.1039/c2cs35292c10.1039/c2cs35292c ↗
21. 10.1126/science.118537210.1126/science.1185372 ↗
22. 10.1016/j.nanoms.2024.03.00210.1016/j.nanoms.2024.03.002 ↗
23. 10.1002/anie.20231503110.1002/anie.202315031 ↗
24. 10.1039/C8TB01853G10.1039/C8TB01853G ↗
25. 10.1039/D3NA00210A10.1039/D3NA00210A ↗
26. 10.1002/anie.20211617010.1002/anie.202116170 ↗
27. 10.1039/c2cs35145e10.1039/c2cs35145e ↗
28. 10.1002/anie.20070434410.1002/anie.200704344 ↗
29. 10.1021/acsami.2c1124510.1021/acsami.2c11245 ↗
30. 10.1016/j.apsusc.2022.15249610.1016/j.apsusc.2022.152496 ↗
31. 10.1039/C7TB02676E10.1039/C7TB02676E ↗
32. 10.1016/j.cclet.2022.10810910.1016/j.cclet.2022.108109 ↗
33. 10.1016/j.cej.2022.13451110.1016/j.cej.2022.134511 ↗
34. 10.1016/j.seppur.2021.11920010.1016/j.seppur.2021.119200 ↗
35. 10.1016/j.jconrel.2022.05.04710.1016/j.jconrel.2022.05.047 ↗
36. 10.1002/adhm.20220036010.1002/adhm.202200360 ↗
37. 10.1016/j.seppur.2023.12399710.1016/j.seppur.2023.123997 ↗
38. 10.1002/adma.20210063710.1002/adma.202100637 ↗
39. 10.1021/acs.nanolett.5b0038810.1021/acs.nanolett.5b00388 ↗
40. 10.1021/acsami.0c0178910.1021/acsami.0c01789 ↗
41. 10.1038/srep1742210.1038/srep17422 ↗
42. 10.1016/j.apcata.2019.02.00510.1016/j.apcata.2019.02.005 ↗
43. 10.1016/j.cej.2020.12798710.1016/j.cej.2020.127987 ↗
44. 10.1038/ncomms1067210.1038/ncomms10672 ↗
45. 10.1021/acs.accounts.8b0001110.1021/acs.accounts.8b00011 ↗
46. 10.1016/j.bioactmat.2021.10.02310.1016/j.bioactmat.2021.10.023 ↗
47. 10.1016/j.jcis.2023.04.14910.1016/j.jcis.2023.04.149 ↗